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The miR-15/107 group of microRNA genes: evolutionary biology,
cellular functions, and roles in human diseases
John R. Finnerty, PhD*, Wang-Xia Wang, PhD*, Sébastien S. Hébert, PhD, Bernard R.
Wilfred, PhD, Guogen Mao, PhD, and Peter T. Nelson, MD, PhD
Department of Pathology and Division of Neuropathology, University of Kentucky Medical Center
and Sanders-Brown Center on Aging, University of Kentucky, Lexington, KY, 40536 and Boston
University, Biology Department, 5 Cummington Street, Boston, MA 02215
Abstract
The miR-15/107 group of microRNA (miRNA) genes is increasingly appreciated to serve key
functions in humans. These miRNAs regulate gene expression involved in cell division,
metabolism, stress response, and angiogenesis in vertebrate species. The miR-15/107 group has
also been implicated in human cancers, cardiovascular disease, and neurodegenerative diseases
including Alzheimer’s disease. Here, we provide an overview of (1) the evolution of miR-15/107
group member genes, (2) the expression levels of the miRNAs in mammalian tissues, (3) evidence
for overlapping gene regulatory functions by the different miRNAs, (4) the normal biochemical
pathways regulated by miR-15/107 group miRNAs, and (5) the roles played by these miRNAs in
human diseases. Membership in this group is defined on the basis of sequence similarity near the
mature miRNAs’ 5′ end: all include the sequence AGCAGC. Phylogeny of this group of miRNAs
is incomplete so a definitive taxonomic classification (for example, designation as a
“superfamily”) is currently not possible. While all vertebrates studied to date express miR-15a,
-15b, -16, -103, and -107, mammals alone are known to express miR-195, -424, -497, -503, and
-646. Multiple different miRNAs in the miR-15/107 group are expressed at moderate-to-high
levels in human tissues. We present data on the expression of all known miR-15/107 group
members in human cerebral cortical gray and white matter using new miRNA profiling
microarrays. There is extensive overlap in the mRNAs targeted by miR-15/107 group members.
We show new data from cultured H4 cancer cells that demonstrate similarities in mRNAs targeted
by miR-16 and miR-103, and also support the importance of the mature miRNAs’ 5′ seed region
in mRNA target recognition. In conclusion, the miR-15/107 group of miRNA genes is a
fascinating topic of study for evolutionary biologists, miRNA biochemists, and clinically-oriented
translational researchers alike.
Introduction
Here we describe a group of microRNA (miRNA) genes with strong influences on human
biology in health and disease: the miR-15/107 gene group. Basic information about miRNA
genomics, biogenesis, processing, and mRNA target recognition will not be described here
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but many other sources are available1; 2; 3; 4; 5; 6; 7; 8. New data will be presented that
focuses on specific biological aspects of miR-15/107 gene group members including the
expression of individual miRNAs in human brain and their functional overlap in cultured
cells. To provide introductory information about these homologous genes, we will first
review prior studies related to miRNA evolutionary biology.
Heterogeneity and evolution of the miR-15/107 group of miRNA genes
The 5′ end-portion of miRNAs is particularly important determinant of miRNA function 9;
10; 11; 12, and a group of vertebrate miRNAs shows 5′ end sequence similarity and also
many common targets. There are 12 annotated human genes in the miRBase miRNA
Registry13 with the sequence AGCAGC starting at either the first or second nucleotide (nt)
from the 5′ end of the mature (~22nt single-stranded) miRNA, a motif which we refer to as
AGCx2. The human AGCx2 miRNAs are shown in Figure 1, along with a diagram that
demonstrates how the mature miRNAs cluster hierarchically according to sequence
similarity. Half of the AGCx2 human genes (hsa-miR-15a14, hsa-miR-16-114, hsa-
miR-16-215, hsa-miR-103-115, hsa-miR-103-215, and hsa-miR-10715) were originally
identified based on studies in cultured HeLa cervical cancer cells16. The remaining six
AGCx2 miRNA genes were identified in other human-derived cancer cell lines (hsa-
miR-42417, and hsa-miR-64618) or from non-neoplastic tissues (hsa-miR-15b19, hsa-
miR-19520, hsa-miR-49721, and hsa-miR-50321; 22).
Reconstructing the functional evolution of medically-relevant genes can help to predict the
clinical consequences of the sequence variation we observe. However, we are unable to
clearly delineate a taxonomy for the AGCx2 miRNA genes. A gene family is a group of
genes with a common phylogenetic origin and possible functional homology23; 24. As a
practical matter, the reconstruction of gene phylogenies is nearly always based on
incomplete information. The miRBase miRNA Registry25 provides the most definitive
miRNA annotation, yet this miRNA list is a work in progress with additional miRNAs still
unidentified. Compounding the problem of missing data, there is no consensus about how
miRNA gene families (as well as sub-families and superfamilies) should be defined. Current
miRNA classifications recognize distinct miR-15, miR-16, miR-103, and miR-107 families
26; 27; 28; 29; 30; 31.
The known phylogenetic distribution of AGCx2 miRNAs suggests that they are unique to
deuterostomes (a superphylum of animals that includes chordates but not insects or worms),
and the number of AGCx2 genes has increased dramatically within the mammals32; 33; 34.
No such miRNA has been described in a plant or non-chordate animal (Figure 2). Seven of
the 12 AGCx2 miRNAs expressed in humans are widespread within the vertebrata, having
been identified in other primates, rodents, birds, amphibians, and bony fishes. The other five
are apparently mammalian specific, and miR-646 appears in humans and chimpanzees but
has not been found in Rhesus monkeys. MiR-322 has only been identified in mammals other
than humans, so will not be discussed here. Note that all twelve of the human AGCx2
miRNA genes are associated with protein-coding genes, or transcribed pseudogenes,
compared to ~50% of human miRNA genes that reside in intergenic regions35; 36. As can
happen with paralogs that arise via gene duplication, some genes are paired genomically in
tandem: miR-15 paralogs with miR-16 paralogs, miR-424 with miR-503, and miR-497 with
miR-195; these syntenies are evolutionarily conserved.
According to a recent phylogenetic analysis, miR-103 and miR-107 originated in the
common ancestor of deuterostomes; Peterson and co-workers define a miR-103 superfamily
that includes these two genes along with miR-201330. MiR-103 and miR-107 paralogs have
been stable across vertebrate genomes, residing almost always in pantothenate kinase
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(PANK) gene introns. One exception: in the frog, Xenopus tropicalis, miR-103 is in a
PANK gene intron but miR-107 is located intergenically. PANK genes encode polypeptides
that are important in metabolism-related cell functions37 (see below). Intronic miRNAs tend
to be co-expressed with their protein-coding ‘mother’ genes although this is not always the
case38; 39; 40.
A miR-15 superfamily, comprising miR-15a, miR-15b, miR-16, miR-195, miR-322,
miR-424, miR-457, and miR-497 are hypothesized to have evolved in the common ancestor
of vertebrates 32; 33; 34. There are two miR-15/16 clusters in mammals. Many vertebrate
species have three or more paralogs of miR-15 and miR-16 as shown in Figure 2. The
location of miR-15a/16 in the DLEU2 (“deleted in leukemia 2”, a non-coding transcript that
affects cell proliferation41; 42) gene seems to have evolved more recently. It is tempting to
speculate that the physical location of miR-15/16 (located within chromatin/DNA and cell
proliferation-related genes SMC4 and DLEU2) and miR-103/107 (located within cellular
metabolism-related PANK genes) along with their known overlap in targets (see below),
provide clues that these genes serve functional roles linked to cross-talk between the key
cellular functions of cell division and metabolism.
Cephalochordates are generally regarded as the sister group of vertebrates 6, and the model
cephalochordate, Branchiostoma floridae, expresses four miRNAs with 5′-end AGCAGC
motifs6; 43 (Figure 3). The B. floridae mir-2013 is most similar to human miR-107, with
17/23 (74%) of the mature miRNAs’ nts matching exactly, including the 5′-end eight nts. A
comparison between the different pre-miRNAs in Danio rerio and B. floridae show that the
zebrafish miR-103 and miR-107 cluster in an intermediate position between the B.floridae
pre-miRNAs and the zebrafish miR-15/16 pre-miRNAs 44.
Urochordates are generally regarded as the sister group to vertebrates plus cephalochordates.
The sea squirt Ciona intestinalis appears to have lost (or never expressed) miR-103 and
miR-107 genes. C. intestinalis has only been shown to express a single AGCx2 miRNA,
which resembles miR-15 and resides in an intron of an SMC4 (“structural maintenance of
chromosomes 4”) ortholog. The genomic location in C. intestinalis SMC4 is significant
because as stated above, a miR-15 ortholog also is expressed in a SMC4 intron in
vertebrates. SMC4 is an essential, evolutionarily-conserved ATPase that participates in
DNA/chromatin dynamics45; 46. More distantly-related species such as Drosophila and
Caenorhabditis express no AGCx2 miRNAs.
We conclude that the origins of the miR-15 and miR-107 genes remain an unsolved puzzle
for now. We cannot reject definitively the possibility that the miR-15 superfamily members
had an independent origin in an early vertebrate ancestor, and they have converged in some
respects with a separately-evolved miR-107 superfamily. However, it also is possible that
the miR-15 superfamily and the miR-107 superfamily evolved from a common ancestor
possessing a 5′-end AGCAGC sequence. If so, these miRNAs may exhibit functions that
have been retained from their common ancestor and it would be appropriate to recognize the
“miR-15/107 gene superfamily.” The existence of functional overlap between human
miR-15/-16 and miR-103/-107 genes lends credibility to this hypothesis (see below). In
either case, insights into the biology of the ancestral member of this group of genes could be
gleaned from functional analyses of miRNAs in non-vertebrate deuterostomes. Other
insights can be gained by studying the function and expression of these intriguing miRNAs
in mammals.
Expression of the miR-15/107 group in mammalian tissues
MiRNA profiling experiments have shown that miR-15/107 group miRNAs are expressed at
moderate-to-high levels in many mammalian tissues. Here we are distilling a large,
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sometimes contradictory literature and readers are encouraged to refer to the primary
sources for more detailed information. There are technical challenges in assessing these
genes’ expression levels, and a wide range of methods were used in preparing and profiling
the miRNAs in the various studies. Further, in many miRNA profiling platforms there is
cross-reactions in terms of closely-paralogous mature miRNAs such as miR-103 and
miR-107.
Perhaps due to the abovementioned technical factors, there has been inconsistency among
prior studies in terms of miR-15/107 gene group member expression profiling in mammals.
Figure 4 shows results from a subset of prior studies that evaluated miRNA expression in
multiple mammalian tissues including heart, skeletal muscle, brain, lung, liver, kidney,
spleen, and placenta39; 47; 48; 49; 50; 51; 52. There may be similar expression profiles among
some group members across human tissues (miR-15, miR-16, and miR-195) 39, but this is
not always seen. Some but not all studies have indicated that miR-15/miR-16 expression is
relatively high in hematopoietic cells including T lymphocytes47; 48; 51; 53; 54; 55; 56.
Published data is also discrepant as to whether miR-103/7 levels are highest in brain39; 48;
49; 52; 56; 57 and whether miR-195 is expressed at highest levels in lung47; 56. Nor is there a
clear-cut consensus for the miR-15/107 group member(s) that tend to have highest
expression. The complexity of this situation is illustrated by Ason et al58 who used in situ
hybridization to study embryos from different species, finding that miR-107 is essentially
brain-specific in the Japanese killifish, highly expressed in almost all tissues in chicken, but
neither pattern is observed in mouse. Bargaje et al51 identified a subset of 18 miRNAs that
are “constitutively” expressed in all mammalian tissues. From the miR-15/107 group, only
miR-103 and miR-107 were on this list, which may indicate that the other miRNAs have
more specialized functions. Distilling all these observations, the miR-15/107 gene group of
miRNAs can be described as ubiquitous in that as far as we know there has not been a
human cell type described that lacks expression of at least one miR-15/107 gene group
member.
In order to include some of the more recently annotated miR-15/107 group genes in our
discussion, the results of recent expression profiling of miR-15/107 group members in
human brain samples is displayed in Figure 5 (superior and middle temporal gyri, N=4 each
from nondemented individuals older than age 80). These were evaluated using a locked
nucleic acid (LNA)-based microarray and here raw data numbers from the microarrays are
described. The results were different for gray matter and white matter -- the latter contains
more oligodendrocytes and fewer neurons. Note that miR-16 is the highest-expressing
miRNA according to this platform and is expressed at highest levels in white matter. Using a
different microarray platform we found that miR-107 was the highest expressing group
member in similarly processed brain tissue 59; this discrepancy is not surprising.
Researchers from many laboratories have now found that miRNA profiling results obtained
using different platforms can vary dramatically for individual miRNAs despite good overall
inter-platform correlation60; 61; 62; 63; 64. Notwithstanding these technical issues, an
interesting correlation is observed: the miRNAs apparently expressed at highest levels in
human tissues (miR-15a, miR-15b, miR-16, miR-103, miR-107, and miR-195) include a 7-
nt common sequence: AGCAGCA (see Figure 1).
In addition to tissue- and cell-specific factors, developmental stages constitute another layer
of gene expression complexity. Recall that animal miRNAs were discovered in the context
of stage-specific expression during worm development65; 66; 67. There are altered
expressions of miR-15/107 group members in certain stages of mammalian development
also. For example, miR-15 and miR-16 expression correlates to particular stages in
erythropoiesis26; 68. Assessing archival human brains that had been formalin-fixed and
paraffin-embedded we found that miR-16 expression is highly expressed in early human
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brain development 69. Figure 5B shows the results from Miska et al70, which provides
compelling evidence that multiple miR-15/107 group members have increased expression
levels during early mouse brain development.
We conclude the following about the expression of miR-15/107 group members in
mammalian tissues:
• Expression of multiple miR-15/107 group miRNAs are moderate-to-high across
many tissues including cells derived from mesoderm, ectoderm, and endoderm;
• Gene expression among group members tends not to be purely specific to particular
tissue or cell types;
• MiR-15/107 group gene expression is relatively high in some early developmental
stages;
• In humans the highest-expressing miRNAs tend to be miR-15a, miR-15b, miR-16,
miR-103, and miR-107 (all of which contain the sequence AGCAGCA), with the
caveat that some miRNAs were not assessed in earlier studies. Thus, there are
important similarities between the highly-expressed miR-15/107 group members.
MiR-15/107 group miRNA processing and mRNA targeting
Clues related to the evolution and gene expression of miR-15/107 group members support
the idea of a homologous gene group, but what about the functions of the mature miRNAs?
There is compelling evidence that different members of the miR-15/107 group regulate
overlapping lists of mRNA targets. This is presumably because the AGCAGC(A) sequence
near the miRNAs’ 5′ end controls the mRNA target specificity. Some studies have focused
on the mRNA targeting overlap between the “miR-15/16 group” paralogs such as miR-15a,
miR-15b, miR-16, miR-195, miR-424, and miR-50371; 72; 73. Yet there is also functional
overlap even in the more dissimilar group members, miR-103 and miR-10774; 75. In a
rigorous and systematic analysis, Linsley et al27 performed mRNA-detecting microarray
studies after miRNA transfections in cultured cancer cell lines. They concluded that
“(miR-15a, miR-16, and miR-103) are members of a single miRNA group”. Linsley et al27
also note that transfections with “miR-15a, miR-16, and miR-195 also gave nearly identical
expression profiles, but miR-103 gave an overlapping but distinct profile compared to other
members of this group, consistent with the 1-nt offset of the miR-103 seed sequence.” More
specifically: “Only a subset of [consensus miR-16 responsive] transcripts was regulated by
miR-103 and miR-107. These transcripts were not regulated in cells transfected with miR-16
duplexes having mismatches at positions 2 and 3 or 4 and 5, but their regulation was
unaltered in cells transfected with duplexes with mismatches at positions 18 and 19 and 19
and 20.” 27
We compared experimentally the effects of transfections using different miR-15/107 group
members in cultured cancer cells (Figure 6). Studies were performed using H4
“glioneuronal” cells using methods that we recently described in detail76; 77. For these
experiments, an individual mRNA was considered to be a target of miRNA X if the level of
that mRNA was significantly reduced following a miRNA transfection with miRNA X,
relative to the level of that mRNA after transfection with a Negative control miRNA
(sequence shown in Figure 6). Three transfections were performed for each miRNA. We
found that mRNAs that are knocked down after transfection by miR-107, miR-103, and
miR-16 tend to overlap substantially. Note that in this experiment the correlation was best
(in terms of mRNAs knocked down) between close paralogs miR-103 and miR-107, but
even between miR-103 and miR-195 the correlation was better than to controls. MiR-15b*
was used as a control miRNA because its sequence (roughly antisense to miR-15b) has
similar G/C content. Two additional non-physiological controls (miR-107MUT1 and
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miR-107MUT2; see Figure 6) were used that have been described before75. Inclusion of
these controls helped to strongly support the importance of the miRNA 5′ seed portion in
terms of dictating mRNA targeting specificity, because the miR-107MUT2, lacking the 5′
seed sequence, does not impact the same mRNAs as miR-103 or miR-16. It should be
emphasized that these data describe mRNAs downregulated in lysates following miRNA
transfections, rather than co-immunoprecipitated definitive “targets”, so some of these
downregulated mRNAs may represent downstream effects. However, these results
underscore the appreciable overlap between different miR-15/107 group members in terms
of their biochemical impact.
Before discussing biological pathways and individual targets affected by miR-15/107 group
genes, we note that miRNAs work through multiple distinct mechanisms78; 79; 80; 81; 82.
There are special considerations related to mRNA targeting by genes in the miR-15/107
group. For example, miR-107 may act preferentially by systematically targeting sequences
in mRNAs’ open reading frame, as opposed to their 3′ untranslated region12. It has been
established that miRNAs may target the protein-coding sequence of target mRNAs83, with
~25% of miRNA targets in mouse brain mRNA corresponding to protein-coding sequences
according to high-throughput sequencing of RNA isolated by crosslinking
immunoprecipitation (HITS-CLIP) data84. However, miR-107 is the first example of an
individual miRNA that may recognize protein-coding portions of target mRNAs
systematically. The phenomenon (a focus of ongoing work in the Nelson laboratory) was
discovered using RIP-Chip technique in H4 cells and will require confirmatory studies in
other cells, tissues, and organisms.
Beyond mRNA targeting, there are additional levels of complexity that distinguish the
miR-15/107 gene group. MiR-107 causes feedback inhibition of the entire miRNA
processing machinery by repressing expression of Argonaute proteins with profound global
changes in miRNA processing 77. Martello et al reported that miR-107 also targets Dicer,
the exonuclease that processes precursor miRNAs85. The interplay between miR-107 and
the miRNA-processing machinery is additionally complicated, because the miR-107 gene
contains a specific sequence motif that controls how the precursor miRNA molecule is
processed by Dicer, and thus how the mature miRNA is expressed. This novel mechanism,
with special relevance to miR-107 and only a few other miRNAs, is associated with the
uridylyl transferase protein “TUTase 4” (TUT4)86. It is currently unknown whether these
phenomena relate to the abovementioned tendency of miR-107 to target mRNAs’ protein-
coding sequences. We are also only beginning to understand the complex mechanisms
regulating transcription of genes in the miR-15/107 group42; 87; 88; 89. In sum, the many
unanswered questions pertaining to miR-15/107 group members’ biological chemistry are an
important consideration as we begin to assess the kaleidoscopic extant data about the
hypothesized functions of miR-15/107 gene group members.
The biochemical impact of a well-expressed mature miRNA is thought to relate to the “sum
of its targets”--the aggregate mRNAs targeted weighted by the strength of each interaction.
Computational predictive methods may provide information but these methods entail some
shortcomings; computational algorithms differ amongst themselves and each is anchored in
prior knowledge90; 91. For a bench researcher wishing to prove that a particular miRNA
targets a specific mRNA, the experimental strategies usually involve a combination of the
following:
• miRNA transfection or over-expression→ down-regulation of target (mRNA and/
or protein);
• In vivo or cell culture miRNA knockout/knockdown→ up-regulation of target
(mRNA and/or protein);
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• reporter assays with subcloned 3′UTR sequences help assess sequence specificity
and confirm direct interaction;
• and target(s) co-purify with anti-Argonaute co-immunoprecipitation with or
without RNA cross-linking.
Each of these methods entails both benefits and difficulties. In terms of potential pitfalls, the
physiological relevance and specificity of cell culture miRNA perturbation techniques bears
critical scrutiny due to the intrinsic artificiality of the experiments, and reporter assays tend
to depend on mechanisms that are not identical to the target mRNAs’ biochemical
contexts91; 92; 93; 94. Co-immunoprecipitation methods entail other assumptions (such as the
stability of the miRNA:mRNA particles) and may only capture a subset of miRNA:target
interactions91. High-throughput methods such as HITS-CLIP and PAR-CLIP84; 95; 96 may
be more indicative of the wide web of miRNA effects than lower-throughput tools because
the -CLIP methods identify miRNA recognition sites transcriptome-wide. However, every
current technique for miRNA target identification is at least somewhat biased by current
dogma and there are probably many interactions yet to be identified. In sum, each and every
experimental method – as with each computational method – includes potential limitations.
These caveats are not mentioned out of pessimism but as a reminder that the field of miRNA
biology is still very much in flux with many exciting discoveries ahead. In that spirit, we
provide updates of various “works in progress” pertaining to miR-15/107 group members.
Biological functions of the miR-15/107 group
A. Cell division
Cellular pathways related to mitosis in vertebrate species are partly regulated by miRNAs in
the miR-15/107 gene group. Most studies have focused on the impact of miR-15 and miR-16
paralogs on cell division, but other miR-15/107 group members have also been studied in
this context. Linsley et al27 described this group of miRNAs as the “miR-16 group” and
noted that miR-15a and miR-16 (and to a lesser extent miR-103) target a highly
disproportionate number of cell cycle genes and transfection with these miRNAs leads to
G0/G1 arrest. Specifically, for miR-103, miR-15a, and miR-16, the percentage of targets
that were involved in cell cycle regulation were 12%, 14%, and 22% respectively as
determined using microarray data after miRNA transfection with correlation to GO process
terms, and these percentages were much higher than would have been expected by chance27.
Other labs have confirmed that miR-15/107 group members (again usually focusing on
miR-15 and miR-16) target cell cycle-related genes (and see below) 27; 28; 42; 97; 98; 99.
MiR-107 transfection also leads to decreased rates of cell division with cell cycle arrest 100.
The biological significance of miR-15/107 gene group-mediated cell cycle arrest is still not
known but is an area of active enquiry partly because of the obvious implications in cancer
biology as discussed below.
B. Cellular metabolism and stress
Numerous lines of evidence indicate that miR-15/107 group genes participate in pathways
involved in cellular metabolism. Tang et al101 studied miRNA expression changes in
response to glucose, using a cDNA array to test the effects of 20 mM pyruvate, 1 or 25 mM
glucose in the cell medium of pancreatic β-cell line MIN6. A handful of miRNAs were up-
regulated following increased extracellular glucose, including miR-107. We subsequently
confirmed this effect of glucose on miR-107 expression using a nearly identical
experimental design but with cultured H4 cells75. MiR-107 is also up-regulated in cells
exposed to folate deficiency102, and dietary intake of various lipids altered specifically
miR-107 expression in the colonic epithelium and cancerous tissue from mice103. Further,
mice forced to perform endurance exercise had over 50% increased miR-107 expression in
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quadriceps femoris muscle tissue relative to a sedentary control group (this was the largest
increase of any miRNA tested)104.
There are other hints that the miR-15/107 group genes are involved in metabolic pathways.
In vertebrate species, miR-103 and miR-107 paralogs reside in introns of genes that also
encode PANK. PANK enzymes catalyze the universal rate-determining step in the formation
of Coenzyme A (CoA). CoA participates in many metabolic reactions105; 106. MiR-103/107
paralogs and PANK genes may be coordinately transcribed gene products with synergistic
effects in regulating cellular Acetyl-CoA levels37. Bioinformatics predict that miR-103/107
paralogs exhibit an exceptional tendency to target mRNAs in a pattern suggestive of synergy
with PANK function. Like PANKs, miR-103/7 may function to increase acetyl-CoA levels
available for the Krebs Cycle, and miR-103/7 may also inhibit the synthesis and metabolism
of cellular lipids37. Although the research to date cannot be fully harmonized into a unitary
framework, miR-15/107 group members clearly are both responsive to, and impactful on,
metabolic pathways in human cells.
It may be artificial to consider biological mechanisms separately from each other because in
a cellular context these pathways interact dynamically. For example, perturbations in
cellular metabolism can cause cell stress and vice versa. Multiple experimental stress
paradigms are associated with changed expression of miR-15/107 group members. In
cultured cells, miR-16 expression increases after ultraviolet light damage and then seems to
participate in regulating the DNA-damage response and cell division machinery107. It has
also been shown that exposure to mice of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX), a
common environmental toxicological contaminant, led to decreased miR-15 and miR-16
expression108. Members of the miR-15/107 group have not been shown to be aberrantly
regulated in heat stress109 which may indicate a more focused cellular role. MiR-107
expression is down-regulated following rodent traumatic brain injury (TBI)110. We have
found that TBI-related miR-107 down-regulation may trigger increased GRN expression in
mouse hippocampi after TBI75, which may be an adaptive response in that context. The
miR-15/107 group may also help regulate cells’ response to ischemic stress: miR-107 and
miR-424 are downregulated in hypoxia111; 112, and miR-15a and miR-497 may help cells
respond to oxygen deprivation in vivo and cell culture models113; 114. It remains to be seen
how these cell stress pathways relate to the other physiological pathways miR-15/107 group
members participate in.
C. Angiogenesis
An exciting recent discovery is the connection between miR-107 and angiogenesis.
Angiogenesis, the dynamic process of growing new small blood vessels from existing
vessels, is directly relevant to development, neoplasia, neurobiology, and various healthy
responses to stress. Yamakuchi et al88 reported that miR-107 is regulated transcriptionally
by P53 protein and in turn miR-107 inhibits HIF-1beta (also known as aryl hydrocarbon
receptor nuclear translocator, ARNT). Through this pathway, miR-107 regulates colon
cancer tumor growth through a mechanism related to angiogenesis. This study provides
insights into upstream regulation of miR-107: agents were identified that up-regulate
miR-107 expression through specific p53-responsive promoter regions. Thus, a small non-
coding RNA neither necessary nor sufficient to subserve any cellular function is
hypothesized to represent a key regulatory intermediary connecting p53 expression,
hypoxia, angiogenesis, and the clinical-biological behavior of colon cancer. These changes
may be synergistic with other miR-15/107 group members. For example, it has been shown
that miR-16 can regulate VEGF strongly in angiogenesis115. As in other important
biological processes, it can be assumed that miRNAs in addition to those of the miR-15/107
group play roles in angiogenesis. Specifically, miR-17-92 cluster, miR-378, miR-143,
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miR-145, miR-93a, miR-27b, miR-130a, let-7f, miR-221, and miR-222 have been shown to
participate in blood vessel development in normal and/or tumor tissues116; 117.
In summary, the ubiquitously expressed miR-15/107 gene group may help orchestrate gene
expression adaptively in boundary areas between important human cellular pathways (e.g.,
cross-talk between hypoxia with angiogenesis, and linking cell proliferation with metabolic
needs). The known functions of this miRNA gene group dovetail intriguingly with the
hypothesis that miRNAs provide cells with a “safeguard against turmoil”118 by regulating
the stability and translation of mRNA. However, any adaptive mechanism can go awry.
Thus it comes as no surprise that dysregulation of miR-15/107 group gene expression may
contribute to, or even cause, human diseases.
Human diseases
A. Neoplasia
An important role for genes in the miR-15/107 gene group has been described in human
cancers. Multiple miRNAs from this group have been implicated, spanning a broad range of
tumor types. Table 1 summarizes miR-15/107 group gene expression changes that have been
found in human neoplastic conditions. In seminal studies, Calin et al119; 120; 121 established
that the miR-15a and miR-16 tandem gene locus was the important genomic susceptibility
factor within the minimal deletion region that determines susceptibility to chronic
lymphocytic leukemia (CLL), as had been hinted at by Lagos-Quintana et al20. Subsequent
studies have produced a compelling corpus of experimental evidence to suggest that
miR-15a/miR-16 constitute key tumor suppressors whose deletion contribute to cancer.
Genes with mRNAs targeted by miR-15a and miR-16, and thought to have clinico-
biological impact for CLL patients, include BCL-2, CCND3, CCNE1, CDK6, CAPRIN1,
and HMGA127; 28; 42; 97; 98; 99. This is an active area of ongoing research and recent
reviews are available122; 123; 124.
The roles of miRNAs in cancer can provide new insights into disease mechanisms and the
rich complexity of mammalian gene regulation. Lee et al reported that promoter methylation
may induce down-regulation of miR-107 in pancreatic carcinomas89. We also note that
granulin (GRN), which is regulated by miR-15/107 gene group members, is an active
mitogen and growth factor relevant to many cancers 125; 126; 127; 128; 129; 130. It remains to
be seen if the impact of miR-107 in pancreatic and other cancers is mediated partly through
GRN. Unlike the case for CLL, pancreatic carcinoma, and other cancers, miRNAs in the
miR-15/107 group are up-regulated in some other cancers such as cervical carcinoma (Table
1). This is compatible with the hypothesis that miRNAs can act as either tumor suppressors
or oncomirs131; 132; 133. Providing yet another layer of complexity in cancers as in other
conditions, the degree of functional redundancy among the different members of the
miR-15/107 group is an important, unresolved, and deceptively complex issue.
B. Neurodegenerative diseases
MiRNAs may have direct relevance to human neurodegenerative diseases including
Alzheimer’s disease (AD), Parkinson’s disease, and frontotemporal dementias (FTD)134;
135; 136. Members of the miR-15/107 group have been shown to be downregulated in AD by
at least three different laboratories 59; 137; 138. We studied the cerebral cortical gray matter
of aged humans and found that miR-107 is downregulated very early in AD pathogenesis59.
This finding was recently validated using a different group of brain samples139. MiR-107
targets the beta-amyloid cleavage enzyme 1 (BACE1) gene so the miRNA down-regulation
may have important pathogenetic consequences59; 103. Yet the physiological significance of
the miR-107 downregulation in AD brains has not been systematically tested. Noren Hooten
et al compared miRNA expression in young versus old individuals’ blood mononuclear cells
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by real-time RT-PCR analysis to test aging-related differences, and found that two of the
nine miRNAs significantly decreased in aged individuals were miR-103 and miR-107140.
The link between decreased miR-103/107 expression and aging merits further study because
age is the most significant risk factor for AD. As noted above, miR-107 and other group
members strongly regulate the expression of the GRN gene75. This targeting depends on
elements in the open reading frame of GRN mRNA. GRN is a susceptibility gene for
FTD141; 142 and we found that the regulation may also be relevant to neuroinflammation and
the brain response to traumatic brain injury. Two laboratories independently reported that
miR-15a is downregulated in AD although these studies employed different technical
parameters137; 138. Members of the miR-15/107 group are also predicted to target the
neurodegeneration-related genes such as the β-amyloid precursor protein and α-
synuclein136; 143. In addition, miR-15/107 group members seem involved in the fine-tuning
of tau phosphorylation (Hébert et al., unpublished data). The findings in AD may tie in with
studies that have suggested that miR-15/107 group member miR-195 may regulate the
important brain growth factor BDNF with relevance to schizophrenia72; 144; 145. We note
that miRNAs outside the miR-15/107 gene group, including miR-29a/b, miR-128,
miR-146a, and others have also been shown to have possible relevance to AD
pathogenesis134; 138; 146; 147; 148; 149; 150; 151; 152; 153; 154. As with other conditions, it is
not known how targeting by different miRNAs overlaps or interacts with the function of
individual miR-15/107 group members in the context of neurodegenerative diseases.
In addition to the miRNA expression down-regulation in AD brains, there are other
connections between the miR-15/107 gene group and neurodegenerative diseases. PANK2,
which harbors an intronic miR-103 gene, is the susceptibility gene for a separate
neurodegenerative disease, pantothenate kinase-associated neurodegeneration (PKAN)155.
PKAN is characterized neuropathologically by progressive brain atrophy with iron pigment
deposition and axonal spheroids mostly in subcortical structures. Intriguingly, the brains of
some PKAN patients harbor neurofibrillary tangles similar to those seen in AD patients’
brains156; 157. We conclude that it is unclear whether miR-15/107 group members
participate causally in neurodegenerative diseases; however, there are already numerous
intriguing connections between the expression of the miR-15/107 gene group members and
the manifestations of neurological diseases.
C. Heart disease
MiR-15/107 group members are among a subset of human-expressed miRNAs that have
been implicated in cardiovascular disease. Most of this research has focused on miR-195.
MiR-195 is up-regulated during cardiac hypertrophy and conversely over-expressing
miR-195 in murine cardiomyocytes led to fatal dilated cardiomyopathy158. An recent review
on the roles of miRNAs in cardiovascular disease is available30.
Summary and Conclusions
Research on the miR-15/107 gene group is less than a decade old but there is compelling
evidence that these genes play essential roles in human biology (Figure 7). MiR-15, miR-16,
miR-103, and miR-107 are stably situated in the genomes of vertebrates; however, the
evolutionary biology of these miRNAs is still incompletely understood. Moderate-to-high
expression of multiple miR-15/107 gene group members has been observed in most human
tissues, with increased expression in particular tissues and at earlier stages of development.
The miR-15/107 group genes that are relatively highly expressed in humans include the
sequence AGCAGCA at or near the 5′ seed region of the mature miRNAs, and this sequence
appears to be a strong determinant of mRNA target selection. Functionally, miRNAs in this
gene group serve fundamental roles in human tissues. Some of these biological functions
occur via novel mechanisms including systematic targeting of mRNA target protein coding
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sequences. Laboratory data dovetail with evidence from evolutionary biology suggesting
that miR-15/107 group members could provide some sort of link between the mechanisms of
cell division and metabolism. MiR-15, miR-107, and their paralogs are dysregulated in some
human diseases and provide potential therapeutic targets. Although there has been
substantial recent scientific progress, much more work remains to be done in studying these
genetic regulators whose complexity and impact are enhanced by functional synergy
between different miRNA genes.
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Figure 1.
Members of the miR-15/107 miRNA gene group that are known to be expressed in humans.
The list of genes (top) shows the 5′ AGCAGC sequence highlighted in black. The 5′ portion
of mature miRNAs is known to confer specificity in terms of regulated mRNA targets. Note
that the AGCAGC sequence starts at the first nucleotide (nt) of miR-103 and miR-107 but
the second nt for the other genes in the group (*). Also note, most of the miRNAs highly-
expressed in humans incorporate a 7-nt common sequence AGCAGCA (#). The sequences
of miR-15/107 group members were compared using a web-based alignment tool (GeneBee;
http://www.genebee.msu.su/services/phtree_reduced.html using the “Cluster” algorithm)
that provide an unbiased graphic illustration of their sequence similarity (bottom).
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Figure 2.
Human genomic context including chromosome (Chr) and evolutionary conservation for the
miR-15/107 gene group between human and Pan troglodytes (Chimpanzee; Chp), Macacca
mulatta (Rhesus; Rhes), Mus musculus (Mouse; Mse), Xenopus tropicalis (Frog), Gallus
gallus (Chicken; Chick), Danio rerio (Zebrafish; Fish), Ciona intestinalis (Sea squirt; Ssq),
Drosophila melanogaster (Fruitfly; Fly), and Caenorhabditis elegans (Worm; Wrm).
MiR-15/107 gene group members are only expressed in chordates, and tend to be located
within or near a protein-coding gene or transcribed pseudogene. Mir-103 and miR-107 are
entirely conserved in vertebrates whereas miR-15 and miR-16 show more variability. A
number of miR-15/107 gene group members are mammalian specific and miR-646 is only
known to be shared between humans and chimpanzees. Source: miRBase miRNA registry
13.
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Figure 3.
The miR-15/107 gene group is chordate-specific but exact phylogenetic relationships are
elusive A. Table compares some features of Drosophila melanogaster (Fruitfly; D.mel), the
amphioxus cephalochordate Branchiostoma floridae (Lancelet; B.fl), Danio rerio
(Zebrafish; D.rer), and Homo sapiens (H.sap). Note B. floridae, a relatively close
evolutionary relative of vertebrates, does express four miRNAs with 5′AGCAGC sequence.
B. A phylogenetic tree was created to evaluate the similarities in the sequences of the ~70
nucleotide (nt) pre-miRNA sequences of B. floridae and D.rerio, the former a relatively late-
evolving pre-vertebrate species and the latter a relatively early-evolving vertebrate species.
This phylogenetic tree shows that the miR-103 and miR-107 genes have sequences with
intermediate similarity between the B. floridae pre-miRNAs and the other members of the
gene group expressed in D.rerio. C. In addition to the apparent homology of the pre-
miRNAs, the sequence of the mature miR-107 has the closest similarity to mature B.
floridae miRNAs. Note that between vertebrates’ miR-107 and B. floridae bfl-mir-2013
17/23 (74%) of the mature miRNAs’ nts matching exactly.
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Figure 4.
Expression profiling of selected miR-15/107 gene group members from prior studies in
human and mouse tissues. Profiling was performed from heart (Ht), skeletal muscle (M),
brain (Br), liver (Li), lung (Lu), kidney (Ki), spleen (Sp), and placenta (Pl). The amount of
miRNAs expressed is displayed in a semi-quantitative way from negligible/nondetected to
very high expression. White squares indicate that the miRNAs were not evaluated in that
tissue in the cited study. A variety of different profiling platforms is represented: microarray
(MA), northern blots (NB), PCR, and a meta-analysis of other profiling studies (Meta). The
semi-quantitative scoring reflects a subjective interpretation from the primary sources cited
in the right-hand column. The results could not be mapped in a purely quantitative manner
due to the nature of the data (for example, NBs yield no quantitative readout), known
differences in dynamic ranges, and differential specificities to individual miRNAs. Note that
there is no obvious tissue-specific pattern of expression that has been found across the
different studies. However, the multiple miR-15/107 gene group members are consistently
found to be expressed in multiple mammalian tissues.
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Figure 5.
Raw microarray data from mammalian brain experiments help illustrate particular aspects of
miR-15/107 gene group member expression. A. Results of a new experiment using the
LNA-microarray including the relatively recently characterized genes miR-497, miR-503,
miR-424, and miR-646. These data include readings from four aged nondemented persons
and the RNA was isolated from the human superior and middle temporal gyri (Brodmann
Areas 21 and 22). White matter and gray matter were dissected and analyzed separately.
Note that all the highly-expressed miRNAs in mammals include the sequence AGCAGCA
at the 5′ end (see Figure 1). Also note that the gray matter and white matter have different
expression for some miRNAs (especially miR-15a, miR-15b, miR-16 which are more highly
expressed in white matter). B. Microarray results at different developmental time points
from the microarray study by Miska et al 70. Mouse brains were studied at embryonic day
12.5 and 17.5, postnatal days 4 and 18, and adults. Note that most members of the
miR-15/107 gene group had highest expression at some pre-adult developmental stage. The
data for miR-103 and miR-195 (as shown with *) are averages of two different results.
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Figure 6.
There is considerable overlap in the mRNAs targeted by various miR-15/107 gene group
members in cultured H4 glioneuronal cancer cells. Transfections with “RIP-Chip”
experimental design were performed as previously described in detail 75; 77. Briefly, H4
cells (American Type Culture Collection, Manassas, VA), were cultured under the vendor’s
recommended conditions and plated at a density of 2.5×106/10cm plate a day before
transfections. Cells were transfected with 25 nM of exogenous RNA duplexes (Ambion,
Austin, TX) with sequences shown on bottom, using RNAiMAX (Invitrogen, Carlsbad, CA)
according to manufacturer’s instructions. Transfections with “miR-107MUT” artificial
miRNAs was recently described75. Cells were harvested 48 hr after transfection, the RNA
was isolated, converted to cDNA and profiled using Affymetrix 1.0 ST Gene microarrays
according to manufacturer’s instructions. A total of 21,898 annotated genes were profiled.
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Genes were evaluated in which mRNA levels were lower after miR-103 transfection
(N=1484 genes; blue bars) or after miR-16 transfections (N= 945 genes; red bars) relative to
the “Neg control” miRNA transfections (N=3 biological replicates for each transfection).
Comparisons were performed using unpaired Student’s t-test with a P<0.01 cutoff. Note that
a majority of genes knocked down by miR-103 were also knocked down by close paralog
mir-107 and the miR-107MUT2 reagents, and also miR-16 and miR-195. Similarly, genes
knocked down by miR-16 tended to also knocked down after miR-195 and somewhat less so
with miR-103, miR-107, and miR-107MUT2 but not controls. These results strongly support
the importance of the 5′ AGCAGC sequences in determining which mRNAs are targeted by
genes in the miR-15/107 gene group.
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Figure 7.
Summary cartoon regarding the regulation and function of the miR-15/107 gene group.
Upstream positive regulation has been documented for glucose (through unknown
transcription factors) and P53 with the caveat that each miRNA is transcriptionally activated
via differing mechanisms. Suppression of miR-15/107 gene group member expression can
occur in cell stress and trauma, and secondary to promoter methylation or MYC. The normal
functions of miR-15/107 gene group members seem to include roles in cell division,
angiogenesis, and metabolic pathways. Dysfunction in miR-107 expression may contribute
to neoplasia, neurodegeneration, cardiovascular dysfunction, and other diseases.
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Table 1
MiR-15/107 gene group may be potential cancer prognostic biomarkers, either up-regulated (“oncomiRs”) or
down-regulated (tumor suppressors) in tumor cells
miRNA expression is a possible prognostic biomarker Reference(s)
miR-16, miR-195 Esophageal carcinoma 159
miR-15a, miR-16 Myelodysplastic syndrome 160
miR-16 Acute lymphoblastic leukemia 161
miR-103/7 Esophageal carcinoma 162
miR-195 Adrenocortical carcinoma 163
miR-15b Hepatocellular carcinoma 164
miRNA expression increased in tumor vs. normal tissues
miR-16 Head and neck carcinoma 165
miR-16 Renal cell carcinoma 166
miR-15b, miR-16 Cervical carcinoma 167
miR-503 Retinoblastoma 168
miR-424 Colonic carcinoma 169
miR-15b Colonic carcinoma 170
miR-15b Malignant melanoma 171
miRNA decreased in tumor vs. normal tissues
miR-15a, miR-16 Prostatic carcinoma 172; 173; 174
miR-15a, miR-16 Chronic lymphocytic leukemia 120; 175
miR-15a, miR-16 Non-small cell lung carcinoma 97
miR-15a, miR-16 Pituitary adenomas 176; 177
miR-15a, miR-16 Ovarian carcinoma 178; 179; 180
miR-107 Colonic carcinoma 103
miR-107 Head and neck carcinoma 181
miR-107 Acute promyelocytic leukemia 182
miR-107 Pancreatic carcinoma 89; 183
miR-107 Tongue squamous cell carcinoma 184
miR-195 Hepatocellular carcinoma 185
miR-195 Bladder carcinoma 186
miR-195 Gastric carcinoma 187
miR-195 Chronic lymphocytic leukemia 188
mir-195, miR-397 Primary peritoneal carcinoma 189
miR-497 Male breast carcinoma 190
miR-503 Parathyroid carcinoma 191
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